Description
AZD-1152 inhibits aurora kinases B and C (AurB, AurC), preventing mitotic spindle formation and proper completion of mitosis. This compound exhibits anticancer chemotherapeutic activity and is currently in clinical trials as a potential treatment for cancers with solid tumors. In acute myelogenous leukemia (AML) and acute lymphocytic leukemia (ALL) cells, AZD-1152 induces apoptosis, inhibiting proliferation. AZD-1152 also induces apoptosis in glioma cells, inhibiting proliferation in vitro and tumor growth in vivo.
References
Hartsink-Segers SA, Zwaan CM, Exalto C, et al. Aurora kinases in childhood acute leukemia: the promise of aurora B as therapeutic target. Leukemia. 2013 Mar;27(3):560-8. PMID: 22940834.
Diaz RJ, Golbourn B, Shekarforoush M, et al. Aurora kinase B/C inhibition impairs malignant glioma growth in vivo. J Neurooncol. 2012 Jul;108(3):349-60. PMID: 22382783.
Boss DS, Witteveen PO, van der Sar J,et al. Clinical evaluation of AZD1152, an i.v. inhibitor of Aurora B kinase, in patients with solid malignant tumors. Ann Oncol. 2011 Feb;22(2):431-7. PMID: 20924078.
